Reducing call-to-needle times: the critical role of pre-hospital thrombolysis
Authors:
Open Access
- 1 October 2004
- journal article
- research article
- Published by Oxford University Press (OUP) in QJM: An International Journal of Medicine
- Vol. 97 (10) , 655-661
Abstract
Background: Current guidelines recommend that patients with acute myocardial infarction should receive thrombolysis within 60 min of seeking professional help. Aim: To compare current rates of pre-hospital thrombolysis in Grampian with historical data, and assess the effect of pre-hospital thrombolysis on the proportion of patients achieving ‘call-to-needle’ times within national guidelines. Design: Prospective audit. Methods: Data were collected on all patients (n = 535) admitted to the coronary care unit and thrombolysed, either in hospital or in the community from July 2000 to June 2002, using standardized forms. Results: One hundred and thirty-three patients (25%) received pre-hospital thrombolysis and 402 (75%) received in-hospital thrombolysis. This compares with a 19% (195/1046) pre-hospital thrombolysis rate in the mid-1990s (p = 0.005). Median ‘call-to-needle’ times were 45 min for pre-hospital thrombolysis and 105 min for patients who received in-hospital thrombolysis (p < 0.001). Only 24% (96/396) of patients receiving in-hospital thrombolysis were treated within the recommended guideline, vs. 79% (88/111) of pre-hospital thrombolysis patients (p < 0.001). Discussion: Pre-hospital thrombolysis rates in Grampian are increasing. Administration of thrombolysis in the community greatly increases the proportion of patients achieving a ‘call-to-needle’ time of 60 min, with a median time saving of ∼1 h.Keywords
This publication has 22 references indexed in Scilit:
- Safety and feasibility of prehospital thrombolysis carried out by paramedicsBMJ, 2003
- Prospective observational cohort study of time saved by prehospital thrombolysis for ST elevation myocardial infarction delivered by paramedicsBMJ, 2003
- Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarctionThe Lancet, 2001
- Myocardial infarction redefined—a consensus document of The Joint European Society of Cardiology/American College of Cardiology committee for the redefinition of myocardial infarctionJACC, 2000
- The pre-hospital management of acute heart attacks. Recommendations of a Task Force of the The European Society of Cardiology and The European Resuscitation Council,European Heart Journal, 1998
- Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hourThe Lancet, 1996
- Acute myocardial infarction: pre-hospital and in-hospital management: The Task Force on the Management of Acute Myocardial Infarction of the European Society of CardiologyEuropean Heart Journal, 1996
- Guidelines for General Practitioners Administering ThrombolyticsDrugs, 1995
- Having of mortality at 1 year by domiciliary thrombolysis in the grampian region early anistreplase trial (GREAT)JACC, 1994
- Feasibility, safety, and efficacy of domiciliary thrombolysis by general practitioners: Grampian region early anistreplase trial. GREAT Group.BMJ, 1992